Lucid Diagnostics (LUCD) Common Equity (2020 - 2026)

Lucid Diagnostics has reported Common Equity for 7 years, with the latest figure at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 174.39% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 174.39% YoY), and the FY2025 full-year result was $10.9 million, up 102.86% from the prior year.
• Common Equity for Q1 2026 stood at $4.0 million, down from $10.9 million in the prior quarter.
• The five-year high for Common Equity was $46.5 million in Q1 2022, with the low at -$5.4 million in Q1 2025.
• Historically, Common Equity has averaged $15.1 million across 5 years, with a median of $11.9 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity jumped 384.07% — and 2025, when it tumbled 145.21%.
• Lucid Diagnostics' Common Equity stood at $23.0 million in 2022, then tumbled by 110.03% to -$2.3 million in 2023, then jumped by 333.28% to $5.4 million in 2024, then surged by 102.86% to $10.9 million in 2025, then plunged by 63.42% to $4.0 million in 2026.
• The last three Common Equity figures came in at $4.0 million (Q1 2026), $10.9 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.